SETTING: Data on the long-term use of linezolid (LZD) in the treatment of drug-resistant pulmonary tuberculosis (DR-PTB) are limited. OBJECTIVE: To assess safety, tolerability and efficacy of LZD-containing regimens for the treatment of DR-PTB in the country of Georgia. DESIGN: A retrospective study was conducted among DR-PTB patients receiving LZD 600 mg/day as part of newly implemented regimens (bedaquiline or delamanid, repurposed and second-line drugs) from July 2014 to October 2015 in programmatic conditions and following WHO recommendations. RESULTS: One hundred mostly male (82%) patients with a median age of 33 years received LZD. Most patients (77%) had previously been treated for TB; 57% had extensively drug-resistant TB. The median duration of LZD use was 503 days (interquartile range 355-616). LZD-associated adverse events occurred in 12 patients, leading to discontinuation in 4 (2 each due to peripheral neuropathy and cytopenias), and dose reduction to 300 mg/day in 6 cases (4 due to peripheral neuropathy and 2 for cytopenias). Almost all patients (95%) achieved culture conversion and 79% had a successful treatment outcomes. CONCLUSION: Treatment regimens including lengthy LZD use showed fairly good safety and tolerability and were associated with high rates of culture conversion and favorable outcomes.
SETTING: Data on the long-term use of linezolid (LZD) in the treatment of drug-resistant pulmonary tuberculosis (DR-PTB) are limited. OBJECTIVE: To assess safety, tolerability and efficacy of LZD-containing regimens for the treatment of DR-PTB in the country of Georgia. DESIGN: A retrospective study was conducted among DR-PTB patients receiving LZD 600 mg/day as part of newly implemented regimens (bedaquiline or delamanid, repurposed and second-line drugs) from July 2014 to October 2015 in programmatic conditions and following WHO recommendations. RESULTS: One hundred mostly male (82%) patients with a median age of 33 years received LZD. Most patients (77%) had previously been treated for TB; 57% had extensively drug-resistant TB. The median duration of LZD use was 503 days (interquartile range 355-616). LZD-associated adverse events occurred in 12 patients, leading to discontinuation in 4 (2 each due to peripheral neuropathy and cytopenias), and dose reduction to 300 mg/day in 6 cases (4 due to peripheral neuropathy and 2 for cytopenias). Almost all patients (95%) achieved culture conversion and 79% had a successful treatment outcomes. CONCLUSION: Treatment regimens including lengthy LZD use showed fairly good safety and tolerability and were associated with high rates of culture conversion and favorable outcomes.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: D Plachouras; E Giannitsioti; S Athanassia; F Kontopidou; A Papadopoulos; K Kanellakopoulou; H Giamarellou Journal: Clin Infect Dis Date: 2006-09-27 Impact factor: 9.079
Authors: G B Migliori; B Eker; M D Richardson; G Sotgiu; J-P Zellweger; A Skrahina; J Ortmann; E Girardi; H Hoffmann; G Besozzi; N Bevilacqua; D Kirsten; R Centis; C Lange Journal: Eur Respir J Date: 2009-03-12 Impact factor: 16.671
Authors: Myungsun Lee; Jongseok Lee; Matthew W Carroll; Hongjo Choi; Seonyeong Min; Taeksun Song; Laura E Via; Lisa C Goldfeder; Eunhwa Kang; Boyoung Jin; Hyeeun Park; Hyunkyung Kwak; Hyunchul Kim; Han-Seung Jeon; Ina Jeong; Joon Sung Joh; Ray Y Chen; Kenneth N Olivier; Pamela A Shaw; Dean Follmann; Sun Dae Song; Jong-Koo Lee; Dukhyoung Lee; Cheon Tae Kim; Veronique Dartois; Seung-Kyu Park; Sang-Nae Cho; Clifton E Barry Journal: N Engl J Med Date: 2012-10-18 Impact factor: 91.245
Authors: Reynaldo Dietze; David Jamil Hadad; Bryan McGee; Lucilia Pereira Dutra Molino; Ethel Leonor Noia Maciel; Charles A Peloquin; Denise F Johnson; Sara M Debanne; Kathleen Eisenach; W Henry Boom; Moises Palaci; John L Johnson Journal: Am J Respir Crit Care Med Date: 2008-09-11 Impact factor: 21.405
Authors: Russell R Kempker; Maia Kipiani; Veriko Mirtskhulava; Nestani Tukvadze; Matthew J Magee; Henry M Blumberg Journal: Emerg Infect Dis Date: 2015-06 Impact factor: 6.883
Authors: Daniel S Graciaa; Maia Kipiani; Matthew J Magee; Lali Mikiashvili; Ketevan Barbakadze; Nino Bablishvili; Sara C Auld; Wael A Alghamdi; Mohammad H Alshaer; Charles A Peloquin; Zaza Avaliani; Henry M Blumberg; Russell R Kempker Journal: Antimicrob Agents Chemother Date: 2022-08-02 Impact factor: 5.938
Authors: A G C Smith; M Gujabidze; T Avaliani; H M Blumberg; J M Collins; S Sabanadze; T Bakuradze; Z Avaliani; R R Kempker; M Kipiani Journal: Int J Tuberc Lung Dis Date: 2021-08-01 Impact factor: 3.427